Editing Heart Protection Study (section)

==Results==
An outline of the study protocol was published in 1999.<ref>{{Cite journal |year=1999 |title=MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: Early safety and efficacy experience |journal=European Heart Journal |volume=20 |issue=10 |pages=725–41 |doi=10.1053/euhj.1998.1350 |pmid=10329064 |doi-access=free}}</ref> Initial results<ref>{{Cite journal |last=Heart Protection Study Collaborative Group |year=2002 |title=MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial |journal=[[The Lancet]] |volume=360 |issue=9326 |pages=7–22 |doi=10.1016/S0140-6736(02)09327-3 |pmid=12114036 |s2cid=35836642}}</ref> were published in 2002, which indicated that vitamins made little difference in modifying cardiovascular risk, but that simvastatin could significantly reduce the risk of cardiovascular events. Further publications, from 2003 and 2004, were concerned with the efficacy of simvastatin in diabetes patients<ref>{{Cite journal |last=Collins |first=R |last2=Armitage |first2=J |last3=Parish |first3=S |last4=Sleigh |first4=P |last5=Peto |first5=R |last6=Heart Protection Study Collaborative Group |year=2003 |title=MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial |journal=Lancet |volume=361 |issue=9374 |pages=2005–16 |doi=10.1016/s0140-6736(03)13636-7 |pmid=12814710 |s2cid=28111189}}</ref> and preventing stroke.<ref>{{Cite journal |last=Collins |first=R |last2=Armitage |first2=J |last3=Parish |first3=S |last4=Sleight |first4=P |last5=Peto |first5=R |last6=Heart Protection Study Collaborative Group |year=2004 |title=Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20536 people with cerebrovascular disease or other high-risk conditions |journal=The Lancet |volume=363 |issue=9411 |pages=757–67 |doi=10.1016/S0140-6736(04)15690-0 |pmid=15016485 |s2cid=42044530}}</ref> A 2005 paper analyses the cost-effectiveness of a prescribing strategy similar to the one employed in the study.<ref>{{Cite journal |last=Mihaylova |first=B |last2=Briggs |first2=A |last3=Armitage |first3=J |last4=Parish |first4=S |last5=Gray |first5=A |last6=Collins |first6=R |last7=Heart Protection Study Collaborative Group |year=2005 |title=Cost-effectiveness of simvastatin in people at different levels of vascular disease risk: Economic analysis of a randomised trial in 20,536 individuals |journal=The Lancet |volume=365 |issue=9473 |pages=1779–85 |doi=10.1016/S0140-6736(05)63014-0 |pmid=15910950 |s2cid=39040005 |doi-access=free}}</ref>